Stocks Comparison
Cardinal Health vs Cellyan Biotechnology: revenue, profit, margins and growth compared
Cardinal Health brought in $254.2B of revenue in fiscal 2026, Cellyan Biotechnology $20.3M in fiscal 2025. Revenue changed by +14.2% at Cardinal Health and +21.7% at Cellyan Biotechnology on the year before, so Cellyan Biotechnology grew faster. Cardinal Health kept 0.7% of its revenue as net profit, Cellyan Biotechnology -0.1%. Free cash flow was $4.5B at Cardinal Health and $499.3K at Cellyan Biotechnology.
Side by side, latest fiscal year
| CAH | HKPD | |
|---|---|---|
| Fiscal year ended | FY2026 (June 30, 2026) | FY2025 (March 31, 2025) |
| Revenue | $254.2B | $20.3M |
| Revenue growth | +14.2% | +21.7% |
| Net income | $1.7B | -$27.1K |
| Net margin | 0.7% | -0.1% |
| Free cash flow | $4.5B | $499.3K |
| Free cash flow margin | 1.8% | 2.5% |
| Earnings per share (diluted) | $7.23 | -$0.00 |
| Cash | $4.9B | $748.7K |
| Debt | $8.9B | $1.9M |
| Price to earnings | 30.5 | n/a |
| Market value | $51.2B | $5.4M |
| Dividend yield | 0.93% | n/a |
| Rank by revenue in sector | #5 of 646 · Health care | #434 of 646 · Health care |
Over the years
Questions about Cardinal Health and Cellyan Biotechnology
Which is bigger by revenue, Cardinal Health or Cellyan Biotechnology?
Cardinal Health is bigger by revenue: $254.2B in fiscal 2026, against $20.3M for Cellyan Biotechnology in fiscal 2025.
Which keeps more of its revenue as profit, Cardinal Health or Cellyan Biotechnology?
Cardinal Health had a net margin of 0.7% in fiscal 2026; Cellyan Biotechnology had -0.1% in fiscal 2025.
Which grew revenue faster, Cardinal Health or Cellyan Biotechnology?
In their latest fiscal years revenue changed by +14.2% at Cardinal Health and +21.7% at Cellyan Biotechnology.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.